NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

液態切片(液態生物檢體)的全球市場:各癌症、產品、樣品、循環生物標記、地區預測及企業分析

Liquid Biopsy Market Global Forecast by Cancer, Product, Sample, Circulating Biomarkers, Regions, Company Analysis

出版商 Renub Research 商品編碼 982535
出版日期 內容資訊 英文 143 Pages
商品交期: 最快1-2個工作天內
價格
液態切片(液態生物檢體)的全球市場:各癌症、產品、樣品、循環生物標記、地區預測及企業分析 Liquid Biopsy Market Global Forecast by Cancer, Product, Sample, Circulating Biomarkers, Regions, Company Analysis
出版日期: 2021年01月01日內容資訊: 英文 143 Pages
簡介

全球液態切片的市場規模,預計至2026年達31億美元。

液態切片市場,從人體提取組織樣品幾乎無痛,手術伴隨的最小限度疼痛即可是主要的成長要素。但,液態切片因為敏銳度低,有抑制市場成長的可能性。

本報告提供全球液態切片(液態生物檢體)市場相關調查,市場概要,市場動態,各市場區隔及各地區分析,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 市場動態

  • 成長要素
  • 課題

第4章 全球液態切片市場

第5章 市場佔有率-全球液態切片市場

  • 各地區
  • 各癌症
  • 各產品
  • 各循環生物標記

第6章 各地區 -液態切片市場

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第7章 癌症 -液態切片市場

  • 肺癌
  • 乳癌
  • 大腸癌
  • 前列腺癌
  • 其他

第8章 各產品 -液態切片市場

  • 套件、消耗品
  • 器具
  • 服務

第9章 各循環生物標記 -液態切片市場

  • 循環腫瘤細胞(CTC)
  • 循環腫瘤DNA(ctDNA)
  • 細胞外小胞(Evs)
  • 其他生物標記(無細胞DNA等)

第10章 各臨床應用 -液態切片市場

  • 監測
  • 預後
  • 治療診斷
  • 篩選

第11章 各樣品 -液態切片市場

  • 血漿/血清
  • 尿
  • 其他

第12章 企業分析

  • Thermo Fisher Scientific Inc.
    • 概要
    • 產品系列
  • Roche Diagnostics
    • 概要
    • 產品系列
    • 財務分析
  • Bio-Rad Laboratories Inc.
    • 概要
    • 產品系列
    • 財務分析
  • Biocept Inc.
    • 概要
    • 產品系列
  • Biocartis
    • 概要
    • 產品系列
    • 財務分析
  • Myriad Genetics,Inc
    • 概要
    • 產品系列
    • 財務分析
  • Genomic Health
    • 產品系列
    • 財務分析
  • NeoGenomics Laboratories
    • 概要
    • 產品系列
    • 財務分析
  • Qiagen
    • 概要
    • 產品系列
    • 財務分析
目錄

A liquid biopsy is an emerging tool for the diagnosis of cancer disease nowadays. The liquid biopsy involves collecting samples and analysing tumours in the blood to diagnose cancer disease in the human body. Liquid biopsy assists medical practitioners as a source of genomic and proteomic knowledge in cancer patients by early detection of circulating tumour cells, DNA and extracellular vesicles. Currently, liquid biopsy plays a critical role in accelerating and implementing accurate oncology in clinical settings by leading to an improved understanding of tumour heterogeneity and allowing for dynamic control of reactions to care and variations in genomics. According to Renub Research analysis, Global Liquid Biopsy Market is expected to be US$ 3.1 Billion by 2026.

The major growth drivers of liquid biopsies are that while extracting the tissue sample from the human body is much pain-free, it substitutes the pain associated with the procedure. Besides, liquid biopsy is very accurate in detecting tumour cells in the blood of cancer patients. Due to the low sensitivity of liquid biopsy, it acts as the restraint factor in the market's growth.

The key players play an essential role in the liquid biopsy market's growth by launching innovative products. In June 2020, NeoGenomics Inc. launched three liquid biopsy tests for non-small cell lung cancer, solid tumour types, and specific breast cancer. The COVID-19 effect in the liquid biopsy market has been harsh because all patients are taking therapies to treat cancer; since they have a weak immune system, and they are less prone to fight with coronavirus diseases.

Renub Research report titled "Liquid Biopsy Market Global Forecast by Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer & Others), Product (Kits & Consumables, Instruments and Services), Sample (Plasma/Serum, Urine & Others), Circulating Biomarkers (Circulating Tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) & Exosomes), Clinical Application (Monitoring, Theranostics, Prognosis & Screening), Regions (Europe, North America, Latin America, Asia-Pacific and Middle East/Africa), Companies (Roche Diagnostics, Thermo Fisher Scientific Inc., Biocept Inc., Bio-Rad Laboratories Inc., Genomic Health, Biocartis, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories)" provides a detailed analysis of Global Liquid Biopsy Industry.

By Cancer

  • 1. Lung Cancer
  • 2. Breast Cancer
  • 3. Colorectal Cancer
  • 4. Prostate Cancer
  • 5. Others

By Product

  • 1. Kits & Consumables
  • 2. Instruments
  • 3. Services

By Circulating Biomarkers

  • 1. Circulating Tumor Cells (CTCs)
  • 2. Circulating Tumor DNA (ctDNA)
  • 3. Extracellular Vesciles
  • 4. Others

By Sample

  • 1. Plasma/Serum
  • 2. Urine
  • 3. Others

By Clinical Application

  • 1. Monitoring
  • 2. Prognosis
  • 3. Theranostics
  • 4. Screening

By Regions

  • 1. North America
  • 2. Europe
  • 3. Asia-Pacific
  • 4. Latin America
  • 5. Middle East/Africa

All the 9 Companies Studied in the Report have been Studied from three Points

  • Company Overview
  • Recent Development
  • Financial Insight

By Companies

  • 1. Thermo Fisher Scientific Inc.
  • 2. Roche Diagnostics
  • 3. Bio-Rad Laboratories Inc.
  • 4. Biocept Inc.
  • 5. Biocartis
  • 6. Myriad Genetics, Inc.
  • 7. Genomic Health
  • 8. NeoGenomics Laboratories
  • 9. Qiagen

Table of Contents

1. Introduction

2. Executive Summary

3. Market Dynamics

  • 3.1 Growth Drivers
  • 3.2 Challenges

4. Global - Liquid Biopsy Market

5. Market Share - Global Liquid Biopsy

  • 5.1 By Region
  • 5.2 By Cancer
  • 5.3 By Product
  • 5.4 By Circulating Biomarkers

6. Region - Liquid Biopsy Market

  • 6.1 North America
  • 6.2 Europe
  • 6.3 Asia-Pacific
  • 6.4 Latin America
  • 6.5 Middle East & Africa

7. Cancer - Liquid Biopsy Market

  • 7.1 Lung Cancer
  • 7.2 Breast Cancer
  • 7.3 Colorectal Cancer
  • 7.4 Prostate Cancer
  • 7.5 Others

8. By Product - Liquid Biopsy Market

  • 8.1 Kits & Consumables
  • 8.2 Instruments
  • 8.3 Services

9. Circulating Biomarkers - Liquid Biopsy Market

  • 9.1 Circulating Tumor cell (CTCs)
  • 9.2 Circulating Tumor DNA (ctDNA)
  • 9.3 Extracellular Vesicles (Evs)
  • 9.4 Other Biomarkers (cell free DNA,etc)

10. By Clinical Application - Liquid Biopsy Market

  • 10.1 Monitoring
  • 10.2 Prognosis
  • 10.3 Theranostics
  • 10.4 Screening

11. By Sample - Liquid Biopsy Market

  • 11.1 Plasma / Serum
  • 11.2 Urine
  • 11.3 Others

12. Company Analysis

  • 12.1 Thermo Fisher Scientific Inc
    • 12.1.1 Overview
    • 12.1.2 Product Portfolio
  • 12.2 Roche Diagnostics
    • 12.2.1 Overview
    • 12.2.2 Product Portfolio
    • 12.2.3 Financial Insight
  • 12.3 Bio-Rad Laboratories Inc
    • 12.3.1 Overview
    • 12.3.2 Product Portfolio
    • 12.3.3 Financial Insight
  • 12.4 Biocept, Inc.
    • 12.4.1 Overview
    • 12.4.2 Product Portfolio
  • 12.5 Biocartis
    • 12.5.1 Overview
    • 12.5.2 Product Portfolio
    • 12.5.3 Financial Insight
  • 12.6 Myriad Genetics, Inc
    • 12.6.1 Overview
    • 12.6.2 Product Portfolio
    • 12.6.3 Financial Insight
  • 12.7 Genomic Health
    • 12.7.1 Product Portfolio
    • 12.7.2 Financial Insight
  • 12.8 NeoGenomics Laboratories
    • 12.8.1 Overview
    • 12.8.2 Product Portfolio
    • 12.8.3 Financial Insight
  • 12.9 Qiagen
    • 12.9.1 Overview
    • 12.9.2 Product Portfolio
    • 12.9.3 Financial Insight

List of Figures

  • Figure 4-1: Global - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 4-2: Global - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 5-1: By Region - Liquid Biopsy Market Share (%), 2015 - 2020
  • Figure 5-2: By Region - Forecast for Liquid Biopsy Market Share (%), 2021 - 2026
  • Figure 5-3: By Cancer - Liquid Biopsy Market Share (%), 2015 - 2020
  • Figure 5-4: By Cancer - Forecast for Liquid Biopsy Market Share (%), 2021 - 2026
  • Figure 5-5: By Product - Liquid Biopsy Market Share (%), 2015 - 2020
  • Figure 5-6: By Product - Forecast for Liquid Biopsy Market Share (%), 2021 - 2026
  • Figure 5-7: By Circulating Biomarkers - Liquid Biopsy Market Share (%), 2015 - 2020
  • Figure 5-8: By Circulating Biomarkers - Forecast for Liquid Biopsy Market Share (%), 2021 - 2026
  • Figure 6-1: United States Cancers by rates of New Cancer Cases (Male & Female) - 2015
  • Figure 6-2: United States Cancers by rates of Cancer Deaths (Male & Female) - 2015
  • Figure 6-3: Number of cancer deaths in Mexico in 2018, by cancer type (in Thousands)
  • Figure 6-4: North America - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 6-5: North America - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 6-6: Europe - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 6-7: Europe - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 6-8: Asia-Pacific - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 6-9: Asia-Pacific - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 6-10: Latin America - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 6-11: Latin America - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 6-12: Middle East & Africa - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 6-13: Middle East & Africa - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 7-1: Lung Cancer - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 7-2: Lung Cancer - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 7-3: Breast Cancer - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 7-4: Breast Cancer - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 7-5: Colorectal Cancer - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 7-6: Colorectal Cancer - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 7-7: Prostate Cancer - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 7-8: Prostate Cancer - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 7-9: Others - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 7-10: Others - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 8-1: Kits & Consumables - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 8-2: Kits & Consumables - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 8-3: Instruments - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 8-4: Instruments - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 8-5: Services - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 8-6: Services - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 9-1: CTCs - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 9-2: CTCs - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 9-3: ctDNA - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 9-4: ctDNA - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 9-5: Extracellular Vesicles - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 9-6: Extracellular Vesicles - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 9-7: Other Biomarkers - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 9-8: Other Biomarkers - Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 10-1: Monitoring - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 10-2: Monitoring - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 10-3: Prognosis - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 10-4: Prognosis - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 10-5: Theranostics - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 10-6: Theranostics - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 10-7: Screening - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 10-8: Screening - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 11-1: Plasma/Serum - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 11-2: Plasma/Serum - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 11-3: Urine - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 11-4: Urine - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 11-5: Others - Liquid Biopsy Market (Million US$), 2015 - 2020
  • Figure 11-6: Others - Forecast for Liquid Biopsy Market (Million US$), 2021 - 2026
  • Figure 12-1: Roche Diagnostics - Diagnostics Sales (Million US$), 2015 - 2020
  • Figure 12-2: Roche Diagnostics - Forecast for Diagnostics Sales (Billion US$), 2021 - 2026
  • Figure 12-3: Bio-Rad Laboratories - Net Sales (Million US$), 2015 - 2020
  • Figure 12-4: Bio-Rad Laboratories - Forecast for Net Sales (Million US$), 2021 - 2026
  • Figure 12-5: Biocept - Revenue (Million US$), 2015 - 2020
  • Figure 12-6: Biocept - Forecast for Revenue (Million US$), 2021 - 2026
  • Figure 12-7: Biocartis - Net Sales (Million US$), 2015 - 2020
  • Figure 12-8: Biocartis - Forecast for Net Sales (Million US$), 2021 - 2027
  • Figure 12-9: Myriad Genetics - Molecular Diagnostics Revenue (Million US$), 2015 - 2020
  • Figure 12-10: Myriad Genetics - Forecast for Molecular Diagnostics Revenue (Million US$), 2021 - 2026
  • Figure 12-11: NeoGenomics Laboratories - Net Sales (Million US$), 2015 - 2020
  • Figure 12-12: NeoGenomics Laboratories - Forecast for Net Sales (Million US$), 2021 - 2027
  • Figure 12-13: Qiagen - Revenue (Million US$), 2015 - 2020
  • Figure 12-14: Qiagen - Forecast For Revenue (Million US$), 2021 - 2027

List of Tables

  • Table 6-1: Estimated number of people living with cancer: by nation, at the end of 2010, 2015, 2020 and 2030
  • Table 6-2: Cancer Statistics Japan - 2017